Literature DB >> 2898157

Effect of 2-pyrrolidone on the concentration of GABA in rat tissues.

C Fasolato1, A Bertazzon, A Previero, L Galzigna.   

Abstract

The effects of 2-pyrrolidone, a cyclic lactam of GABA, were studied on blood and organ levels of 2-pyrrolidone, GABA, glutamic acid, glutamate decarboxylase (GAD) and GABA-transaminase (GABA-T). When administered i.p., the only significant effects observed were increases of brain and liver 2-pyrrolidone. In contrast, regular oral administration for 7 months produced significant increases of GABA and glutamic acid in brain and of glutamic acid alone in liver while GAD decreased in brain and increased in liver; GABA-T was unchanged. A new method for the synthesis of radioactive 2-pyrrolidone was set up and the enzymatic conversion of 2-pyrrolidone to GABA was measured by an original procedure. The results obtained in vitro by this method on the conversion of 2-pyrrolidone to GABA catalyzed by tissue slices, together with the observed inhibition of the GABA-dependent oxygen consumption by 2-pyrrolidone, partially explain the effects of the oral administration.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2898157     DOI: 10.1159/000138392

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  2 in total

1.  A pilot study comparing the metabolic profiles of elite-level athletes from different sporting disciplines.

Authors:  Fatima Al-Khelaifi; Ilhame Diboun; Francesco Donati; Francesco Botrè; Mohammed Alsayrafi; Costas Georgakopoulos; Karsten Suhre; Noha A Yousri; Mohamed A Elrayess
Journal:  Sports Med Open       Date:  2018-01-05

2.  2-Pyrrolidinone and Succinimide as Clinical Screening Biomarkers for GABA-Transaminase Deficiency: Anti-seizure Medications Impact Accurate Diagnosis.

Authors:  Adam D Kennedy; Kirk L Pappan; Taraka Donti; Mauricio R Delgado; Marwan Shinawi; Toni S Pearson; Seema R Lalani; William E Craigen; V Reid Sutton; Anne M Evans; Qin Sun; Lisa T Emrick; Sarah H Elsea
Journal:  Front Neurosci       Date:  2019-05-08       Impact factor: 4.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.